BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN) from a hold rating to a buy rating in a research note published on Saturday.

A number of other equities analysts also recently issued reports on BMRN. Sanford C. Bernstein dropped their price target on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Bank of America reduced their price objective on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Morgan Stanley increased their target price on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a report on Friday. Royal Bank Of Canada dropped their target price on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Finally, UBS Group restated a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $87.86.

BioMarin Pharmaceutical Stock Up 3.8%

Shares of BioMarin Pharmaceutical stock opened at $63.81 on Friday. BioMarin Pharmaceutical has a twelve month low of $49.26 and a twelve month high of $66.28. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. The company’s 50 day moving average is $58.19 and its 200 day moving average is $57.06. The company has a market cap of $12.33 billion, a price-to-earnings ratio of 172.46, a price-to-earnings-growth ratio of 0.49 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. The business had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.36%. The firm’s revenue was up 20.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.44 EPS. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Research analysts anticipate that BioMarin Pharmaceutical will post 4.22 EPS for the current year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently bought and sold shares of BMRN. Activest Wealth Management purchased a new stake in BioMarin Pharmaceutical in the fourth quarter worth about $26,000. CIBC Private Wealth Group LLC raised its stake in shares of BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after buying an additional 179 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at about $39,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of BioMarin Pharmaceutical during the 3rd quarter valued at about $40,000. Finally, V Square Quantitative Management LLC bought a new position in shares of BioMarin Pharmaceutical during the 4th quarter valued at approximately $45,000. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.